Stock Screener App

Gratuito - Play StoreApp Store

Installare Installare

Dow:

Nasdaq:

S&P 500:

DWTX

$1.284.07%0.05

Dopo l'orario di chiusura: 1.33+0.05 +3.91%

Dogwood Therapeutics Inc (DWTX)

Date: O: H: L: C: Vol:

Dogwood Therapeutics Inc Borsa (DWTX) Ultime notizie

Sealbond Ltd Purchases 4,098,360 Shares of Dogwood Therapeutics at $1.22 Each - Kalkine Media

A 4.1M-share sale by Dogwood Therapeutics (DWTX) is expected to close by October 29. - Stock Titan

Dogwood Announces $5 Million Private Placement with CK Life Sciences Int’l., (Holdings) Inc. - markets.businessinsider.com

Dogwood Therapeutics Raises $5 Million From Sealbond at $1.22; Grants Registration Rights - TradingView

Dogwood Therapeutics secures $5M investment from largest shareholder; shares rise - TradingView

Dogwood Announces $5 Million Private Placement with CK Life Sciences Int’l., (Holdings) Inc. - The Manila Times

A $5 million investment is expected to fund Dogwood through March 2027 as it plans its next pain-drug trial. - Stock Titan

Dogwood Announces $5 Million Private Placement with CK Life Sciences Int’l., (Holdings) Inc. - GlobeNewswire

DWTX 8-K & SEC Filings - Yahoo Finance Australia

H.C. Wainwright reiterates Dogwood Therapeutics stock rating at buy - Investing.com

H.C. Wainwright reiterates Dogwood Therapeutics stock rating at buy By Investing.com - Investing.com Australia

H.C. Wainwright reiterates Dogwood Therapeutics stock rating at buy By Investing.com - Investing.com Nigeria

H.C. Wainwright reiterates Dogwood Therapeutics stock rating at buy By Investing.com - Investing.com India

H.C. Wainwright reiterates Dogwood Therapeutics stock rating at buy By Investing.com - Investing.com Canada

H.C. Wainwright reiterates Dogwood Therapeutics stock rating at buy By Investing.com - Investing.com UK

Dogwood Therapeutics advances Halneuron for che... - Pluang

Dogwood Therapeutics Nears Phase 2b Readout for Halneuron Neuropathic Pain Treatment - TradingView

12 Health Care Stocks Moving In Tuesday's Pre-Market Session - Benzinga

Dogwood Therapeutics Nears Phase 2b Readout for Halneuron Neuropathic Pain Treatment - Yahoo Finance

Dogwood (DWTX) Earnings Reading: The Available Earnings Metric Delivers a Beat in the Current Update; After Earnings: Shares Finish 6.87% Up in the Latest Reading - High Estimate Range - vinanet.vn

Dogwood (DWTX) Update: Records a 6.87% Increase to $2.49 at the Close; Boundary Watch: the Supplied Trading Band Runs From $2.37 to $2.61 in the Latest Session - Impulse Wave - vinanet.vn

Armistice Capital Expands Dogwood Therapeutics Stake Amid Biotec - GuruFocus

Dogwood (DWTX) Quarterly Results: EPS Lands Above Forecast; Market Move: Shares Move 7.79% Lower on the Day - Tax Rate Impact - vinanet.vn

Dogwood (DWTX) Earnings Reading: Profit Per Share Clears Its Benchmark in the Current Update; Latest Reaction - vinanet.vn

Research Analysts Offer Predictions for DWTX Q3 Earnings - MarketBeat

Dogwood to Host Virtual KOL Event to Discuss Halneuron® for the Treatment of Chemotherapy Induced Neuropathic Pain on September 1, 2026 - The Manila Times

Halneuron Has Been Tested on More Than 800 Patients—What’s Next? - Stock Titan

Dogwood to Host Virtual KOL Event to Discuss Halneuron® for the Treatment of Chemotherapy Induced Neuropathic Pain on September 1, 2026 - markets.businessinsider.com

What is HC Wainwright's Forecast for DWTX FY2029 Earnings? - MarketBeat

Dogwood Therapeutics, Inc. (NASDAQ: DWTX) Stock Price, News & Analysis - kalkine.ca

Dogwood Therapeutics, Inc. (NASDAQ: DWTX) Stock Price, News & Analysis - kalkine.com.au

Dogwood Therapeutics, Inc. 2026: Revenue ($14.06M), EPS ($0.34) — 10-Q Summary - TradingView

Dogwood Therapeutics (DWTX) logs $16.5M H1 loss and warns on going concern outlook - Stock Titan

Armistice Capital (DWTX) discloses 9.99% Dogwood Therapeutics ownership in 13G/A - Stock Titan

Maxim Group Maintains Dogwood Therapeutics(DWTX.US) With Buy Rating, Maintains Target Price $15 - Moomoo

Dogwood Therapeutics, Inc. (DWTX) EPS 2025: $7.13 loss per share - Stock Titan

Dogwood Therapeutics (NASDAQ:DWTX) Releases Earnings Results, Misses Estimates By $0.21 EPS - MarketBeat

Form 8K Dogwood Therapeutics Inc For: 13 August By Investing.com - Investing.com Nigeria

Form 8K Dogwood Therapeutics Inc For: 13 August By Investing.com - Investing.com Canada

Form 8K Dogwood Therapeutics Inc For: 13 August By Investing.com - Investing.com India

Form 8K Dogwood Therapeutics Inc For: 13 August By Investing.com - Investing.com UK

Dogwood Therapeutics Reports $11.5 Million Second-Quarter Net Loss - Quiver Quantitative

Dogwood Therapeutics reports Q2 2026 net loss of $11.5M, IPR&D charge of $9.19M; $9.6M cash - TradingView

DWTX: Halneuron Phase 2b trial nears completion as Q2 net loss widens on higher R&D and impairment - TradingView

Dogwood Therapeutics Announces Second Quarter 2026 Financial Results - The Manila Times

Dogwood Therapeutics Announces Second Quarter 2026 Financial Results - Yahoo Finance

Dogwood Therapeutics Announces Second Quarter 2026 Financial Results - GlobeNewswire

Dogwood Therapeutics (DWTX) Rises 2.78% as Buyers Defend Key $1.76 Support - MAMA Signal - vinanet.vn

Dogwood Therapeutics Inc (DWTX) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey

Dogwood Therapeutics Inc (DWTX) Stock News Today - TradingKey

Simile a DWTX

NVCT$18.480.48%

ZVRA$10.280.77%